Table 1: Characteristics
of studies included in the meta-analysis.
Study Title, Author, and Year of
Publication |
Population and Study Design |
Intervention |
Outcomes Measured |
Follow-up Duration |
Evaluation of Bromocriptine in the
treatment of acute severe peripartum cardiomyopathy Sliwa, et al. [16]
|
Total N = 20 patients Mean Age:
26 ± 8 NYHA fc
II: 50% NYHA fc
III/IV: 50% Baseline
LVEF (%): 27 ± 7.9 Randomized Controlled Trial |
Group A (10 patients) Standard HF Therapy: Carvedilol 6.25 mg - 12.5 mg BID; Enalapril 5 mg -
10 mg OD; Furosemide 80 mg - 120 mg OD Group B (10 patients) Bromocriptine 2.5 mg
BID × 2 weeks then OD × 6 weeks on top of Standard HF therapy |
·
Cardiovascular Mortality ·
Left Ventricular Ejection
Fraction ·
Worsening NYHA functional
class III / IV |
·
6
months |
Bromocriptine
in management of peripartum cardiomyopathy: A randomized study on 96 women
in Burkina Faso. Yameogo, et al. [17] |
Total N =
96 patients Mean Age:
29.4 ± 3.4 NYHA fc
III: 28.12% NYHA fc
IV: 71.88% Baseline
LVEF (%): 36.4 ± 5.5 Randomized Controlled Trial |
Group A (48 patients): Standard HF therapy: Captopril 6.25 mg - 25 mg OD Furosemide 80 mg OD Group B (48 patients): Bromocriptine 2.5 mg
BID × 4 weeks on top of standard HF therapy |
·
Cardiovascular Mortality ·
Echocardiographic
parameters: LVEDD, LVESD, TAPSE and LVEF ·
Change in dyspnea |
·
2
weeks ·
1
month ·
3
months ·
6
months ·
12
months |
HF: Heart Failure; LVEF: Left Ventricular
Ejection Fraction; NYHA: New York Heart Functional Class; LVEDD: Left
Ventricular End Diastolic Diameter;
LVESD: Left Ventricular End Diastolic Diameter;
TAPSE: Tricuspid Annular Plane Systolic Excursion.